Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Licenses Cache of Therapeutic Antibodies to Genentech

NEW YORK, Oct. 23 - Incyte Genomics and Genentech have struck a licensing deal that covers patents covering therapeutic antibodies to four proteins discovered by Incyte, the companies said on Tuesday.

Under terms of the agreement, Incyte is entitled to receive clinical development milestone payments for the antibodies and royalties if any are commercialized.

Financial terms of the agreement and the intended clinical uses of the four antibodies were not disclosed.

Separately on Tuesday, Incyte, of Palo Alto, Calif., said it has rescheduled the release of its third-quarter financial statement to Oct. 25. The company will hold a conference call for investors at 9:30 a.m. PDT.

The release date, originally scheduled for Oct. 24, was changed to avoid scheduling conflicts, Incyte said.

Last week, Incyte was sued by Invitrogen in a patent dispute over Invitrogen’s SuperScript form of RNAse H minus reverse transcriptase, which the company said was sold to Incyte under a research-use-only license.

As GenomeWeb reported on Thursday, Carlsbad, Calif.-based Invitrogen said it seeks to have Incyte stop using the product without a commercial license and to stop buying the product from unlicensed third parties.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.